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Dear Editor,
I read with interest the article by Kashani et al, on the use 
of hydroxyurea (HU) in the treatment of chronic hepatitis 
B published in Hepatitis Monthly (1). In their article, the au-
thors performed a limited pilot study and concluded that 
HU  effectively  blocks  HBV  replication.  Favorable  dosing 
schedule, safety profile, and cost make HU a very attractive 
adjunct to the therapeutic armamentarium in a wide range 
of diseases including sickle cell anemia, thalassemia inter-
media and human immunodeficiency virus (HIV) infection 
(2, 3). The potential role of HU in the treatment of HIV infec-
tion was supported first by in vitro experiments and then 
by controlled clinical trials (4). Indeed, an activated cellular 
environment is crucial for the initial phase of the HIV-1 life 
cycle that involves reverse transcription of the viral RNA, 
the establishment of the HIV-1 provirus within host chromo-
somes, and the subsequent production of virions. The arrest 
of the cell cycle in the G1 phase by HU reduces cellular activa-
tion and thus should decrease viral production and overall 
viral burden (5). In all controlled trials assessing treatment 
of HIV, addition of HU to the standard antiretroviral therapy 
(ART) has been compared to ART with or without placebo (4).
Herein, I would like to mention a couple of drawbacks in the 
study design of this article: First of all, for ethical concerns, 
it was better if the authors would have used HU or placebo 
with standard antiviral therapy among patients and control 
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groups, respectively, instead of first treating naïve chronic 
hepatitis B patients with HU. Furthermore, in this study, only 
results of HBV DNA viral load titers in cases are given and no 
information regarding HBe Ag status and liver enzyme pro-
files of the patients which have independent effects on stan-
dard antiviral treatment outcome, are provided. Finally, it is 
not clear if all samples for the HBV DNA viral loads were test-
ed in one laboratory using a similar and standard method. 
There is also not clear whether assessors were blinded to the 
samples. Of course, causal inference for the efficacy of HU in 
the treatment of chronic hepatitis B patients should be ac-
complished through conduction of well-designed random-
ized controlled trials. Nonetheless, pilot studies conducted 
in this field should have enough power to justify conduction 
of future studies.
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